US5217996A
(en)
*
|
1992-01-22 |
1993-06-08 |
Ciba-Geigy Corporation |
Biaryl substituted 4-amino-butyric acid amides
|
IL115995A0
(en)
*
|
1994-11-15 |
1996-01-31 |
Bayer Ag |
Substituted 4-biarylbutyric or 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors
|
TR199700834T1
(xx)
*
|
1995-02-22 |
1998-01-21 |
Novartis Ag |
1-Aril-2-Akilamino ethan bile�ikleri ve bunlar�n n�rokinin olarak �zellikle n�rokinin 1 has�mlar� olarak kullan�mlar�.
|
MY132550A
(en)
|
1996-08-22 |
2007-10-31 |
Novartis Ag |
Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists
|
IL144285A0
(en)
*
|
1999-03-29 |
2002-05-23 |
Bristol Myers Squibb Co |
Pharmaceutical compositions containing a vasopeptidase inhibitor
|
US7468390B2
(en)
*
|
2002-01-17 |
2008-12-23 |
Novartis Ag |
Methods of treatment and pharmaceutical composition
|
RU2334513C3
(ru)
*
|
2002-01-17 |
2017-10-24 |
Новартис Аг |
Фармацевтические композиции, включающие валсартан и ингибиторы нейтральной эндопептидазы (nep)
|
GB0203061D0
(en)
*
|
2002-02-08 |
2002-03-27 |
Novartis Ag |
Organic compounds
|
ATE550656T1
(de)
*
|
2003-08-20 |
2012-04-15 |
Alere San Diego Inc |
Verfahren und zusammensetzungen zur messung biologisch aktiver natriuretischer peptide und zur verbesserung ihres therapeutischen potentials
|
US7781478B2
(en)
*
|
2004-07-14 |
2010-08-24 |
Ptc Therapeutics, Inc. |
Methods for treating hepatitis C
|
US7772271B2
(en)
*
|
2004-07-14 |
2010-08-10 |
Ptc Therapeutics, Inc. |
Methods for treating hepatitis C
|
US8013006B2
(en)
*
|
2004-07-14 |
2011-09-06 |
Ptc Therapeutics, Inc. |
Methods for treating hepatitis C
|
US7868037B2
(en)
*
|
2004-07-14 |
2011-01-11 |
Ptc Therapeutics, Inc. |
Methods for treating hepatitis C
|
MX2007000762A
(es)
|
2004-07-22 |
2007-04-02 |
Ptc Therapeutics Inc |
Tienopiridinas para tratamientode hepatitis c.
|
MY146830A
(en)
*
|
2005-02-11 |
2012-09-28 |
Novartis Ag |
Combination of organic compounds
|
WO2007045663A2
(en)
*
|
2005-10-19 |
2007-04-26 |
Novartis Ag |
Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
|
RU2459809C2
(ru)
*
|
2005-11-09 |
2012-08-27 |
Новартис Аг |
Фармацевтические комбинации антагониста рецептора ангиотензина и ингибитора nep
|
AR057882A1
(es)
*
|
2005-11-09 |
2007-12-26 |
Novartis Ag |
Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
|
EP1903027A1
(en)
*
|
2006-09-13 |
2008-03-26 |
Novartis AG |
Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of NEP inhibitors
|
LT2121578T
(lt)
|
2007-01-12 |
2016-11-25 |
Novartis Ag |
5-bifenil-4-amino-2-metilpentano rūgšties gavimo būdas
|
TW200838501A
(en)
|
2007-02-02 |
2008-10-01 |
Theravance Inc |
Dual-acting antihypertensive agents
|
TWI448284B
(zh)
|
2007-04-24 |
2014-08-11 |
Theravance Inc |
雙效抗高血壓劑
|
TWI406850B
(zh)
|
2007-06-05 |
2013-09-01 |
Theravance Inc |
雙效苯并咪唑抗高血壓劑
|
US7834041B2
(en)
|
2007-09-07 |
2010-11-16 |
Theravance, Inc. |
Dual-acting antihypertensive agents
|
EP2209786B1
(en)
*
|
2007-10-05 |
2013-02-27 |
Verastem, Inc. |
Pyrimidine substituted purine derivatives
|
US8212052B2
(en)
*
|
2007-12-11 |
2012-07-03 |
Theravance, Inc. |
Dual-acting benzoimidazole antihypertensive agents
|
AU2012202949B2
(en)
*
|
2008-01-17 |
2015-01-22 |
Novartis Ag |
Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives
|
PE20091364A1
(es)
*
|
2008-01-17 |
2009-10-13 |
Novartis Ag |
Proceso para la preparacion de inhibidores de nep
|
JP2011518884A
(ja)
|
2008-04-29 |
2011-06-30 |
セラヴァンス, インコーポレーテッド |
二重活性抗高血圧剤
|
CN101607875B
(zh)
*
|
2008-06-17 |
2012-07-25 |
中国石油化学工业开发股份有限公司 |
制造环烷酮的方法
|
EP2334651A2
(en)
|
2008-07-24 |
2011-06-22 |
Theravance, Inc. |
Dual-acting antihypertensive agents
|
CN101774941A
(zh)
*
|
2009-01-13 |
2010-07-14 |
浙江九洲药业股份有限公司 |
2-酰基氨基-3-联苯基丙酸的制备及拆分方法
|
US9468637B2
(en)
|
2009-05-13 |
2016-10-18 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
JP5466759B2
(ja)
*
|
2009-05-28 |
2014-04-09 |
ノバルティス アーゲー |
ネプリライシン阻害剤としての置換アミノ酪酸誘導体
|
CN103896796B
(zh)
*
|
2009-05-28 |
2016-04-27 |
诺华股份有限公司 |
作为脑啡肽酶抑制剂的取代的氨基丙酸衍生物
|
US7956054B2
(en)
|
2009-07-07 |
2011-06-07 |
Theravance, Inc. |
Dual-acting pyrazole antihypertensive agents
|
EP2456762B1
(en)
|
2009-07-22 |
2013-10-16 |
Theravance, Inc. |
Dual-acting oxazole antihypertensive agents
|
JO2967B1
(en)
|
2009-11-20 |
2016-03-15 |
نوفارتس ايه جي |
Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
|
US8481549B2
(en)
*
|
2010-01-19 |
2013-07-09 |
Theravance, Inc. |
Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
|
PT2526088E
(pt)
*
|
2010-01-22 |
2015-11-03 |
Novartis Ag |
Intermediários dos inibidores da endopeptidase neutra e método de preparação dos mesmos
|
EP2609071B1
(en)
|
2010-08-23 |
2016-09-21 |
Novartis AG |
New process for the preparation of intermediates useful for the manufacture of nep inhibitors
|
KR101476937B1
(ko)
|
2010-08-23 |
2014-12-24 |
노파르티스 아게 |
Nep 억제제의 제조를 위한 중간체의 제조 방법
|
ES2702529T3
(es)
|
2010-08-24 |
2019-03-01 |
Novartis Ag |
Una composición farmacéutica para uso en la prevención o tratamiento de la insuficiencia cardíaca en un mamífero que recibe terapia anticoagulante
|
US8673974B2
(en)
*
|
2010-11-16 |
2014-03-18 |
Novartis Ag |
Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
|
US8993631B2
(en)
*
|
2010-11-16 |
2015-03-31 |
Novartis Ag |
Method of treating contrast-induced nephropathy
|
US8586536B2
(en)
|
2010-12-15 |
2013-11-19 |
Theravance, Inc. |
Neprilysin inhibitors
|
AU2011343903B2
(en)
|
2010-12-15 |
2016-06-30 |
Theravance Biopharma R&D Ip, Llc |
Neprilysin inhibitors
|
US8449890B2
(en)
|
2011-02-17 |
2013-05-28 |
Theravance, Inc. |
Neprilysin inhibitors
|
RU2604522C2
(ru)
|
2011-02-17 |
2016-12-10 |
ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи,ЭлЭлСи |
Замещенные аминомасляные производные в качестве ингибиторов неприлизина
|
EP2714660B1
(en)
|
2011-05-31 |
2018-09-26 |
Theravance Biopharma R&D IP, LLC |
Neprilysin inhibitors
|
US8513244B2
(en)
|
2011-05-31 |
2013-08-20 |
Theravance, Inc. |
Neprilysin inhibitors
|
ES2642883T3
(es)
|
2011-05-31 |
2017-11-20 |
Theravance Biopharma R&D Ip, Llc |
Inhibidores de neprilisina
|
TWI560172B
(en)
|
2011-11-02 |
2016-12-01 |
Theravance Biopharma R&D Ip Llc |
Neprilysin inhibitors
|
TWI562986B
(en)
*
|
2012-02-15 |
2016-12-21 |
Theravance Biopharma R&D Ip Llc |
Process for preparing 4-amino-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-pentanoic acid compounds
|
ES2609810T3
(es)
|
2012-05-31 |
2017-04-24 |
Theravance Biopharma R&D Ip, Llc |
Inhibidores de neprilisina donadores de óxido nítrico
|
CN104470521B
(zh)
|
2012-06-08 |
2017-04-12 |
施万生物制药研发Ip有限责任公司 |
脑啡肽酶抑制剂
|
MX356260B
(es)
|
2012-06-08 |
2018-05-21 |
Theravance Biopharma R&D Ip Llc |
Inhibidores de la neprilisina.
|
LT2882716T
(lt)
|
2012-08-08 |
2017-02-10 |
Theravance Biopharma R&D Ip, Llc |
Neprilizino inhibitoriai
|
CA2882771C
(en)
|
2012-08-24 |
2021-02-23 |
Novartis Ag |
Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling
|
AU2014216417B2
(en)
|
2013-02-14 |
2016-05-12 |
Novartis Ag |
Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy
|
NZ710574A
(en)
|
2013-02-14 |
2017-11-24 |
Novartis Ag |
Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
|
US9801882B2
(en)
|
2013-02-17 |
2017-10-31 |
Intra-Cellular Therapies, Inc. |
Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
|
SI2964616T1
(sl)
|
2013-03-05 |
2017-08-31 |
Theravance Biopharma R&D Ip, Llc |
Zaviralci neprilizina
|
CN104230865B
(zh)
*
|
2013-06-13 |
2018-01-09 |
上海翰森生物医药科技有限公司 |
联芳基取代的4‑氨基丁酸衍生物及其制备方法和用途
|
US20160206597A1
(en)
|
2013-08-26 |
2016-07-21 |
Toni Lynne Bransford |
New Use
|
PL3626270T3
(pl)
|
2013-08-26 |
2024-04-08 |
Novartis Ag |
Leczenie chorób sercowo-naczyniowych
|
KR20160113291A
(ko)
|
2014-01-30 |
2016-09-28 |
세라밴스 바이오파마 알앤디 아이피, 엘엘씨 |
네프리리신 저해제
|
AU2015211041B2
(en)
|
2014-01-30 |
2018-11-08 |
Theravance Biopharma R&D Ip, Llc |
5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors
|
CN106795099B
(zh)
*
|
2014-04-10 |
2019-11-26 |
南京奥昭生物科技有限公司 |
用于治疗高血压和心血管疾病的前药和组合物
|
TWI686394B
(zh)
|
2014-08-07 |
2020-03-01 |
美商內胞醫療公司 |
有機化合物
|
CN105622452A
(zh)
*
|
2014-08-27 |
2016-06-01 |
上海翰森生物医药科技有限公司 |
Ahu-377结晶型游离酸及其制备方法和应用
|
CN105461587A
(zh)
*
|
2014-08-27 |
2016-04-06 |
上海翰森生物医药科技有限公司 |
Ahu-377半钙盐晶型及其制备方法和应用
|
CN105367438A
(zh)
*
|
2014-08-27 |
2016-03-02 |
上海翰森生物医药科技有限公司 |
AHU-377α-苯乙胺盐多晶型及其制备方法和应用
|
WO2016029828A1
(zh)
*
|
2014-08-27 |
2016-03-03 |
上海翰森生物医药科技有限公司 |
AHU-377结晶型游离酸、半钙盐、α﹣苯乙胺盐及其制备方法和应用
|
WO2016037098A1
(en)
|
2014-09-04 |
2016-03-10 |
Concert Pharmaceuticals, Inc. |
Deuterated sacubitril
|
PL3218351T3
(pl)
|
2014-11-14 |
2019-12-31 |
Zentiva K.S. |
Sposób wytwarzania, wyodrębniania i oczyszczania farmaceutycznie dopuszczalnych postaci AHU-377
|
CN105693543B
(zh)
*
|
2014-12-15 |
2018-08-10 |
四川海思科制药有限公司 |
沙库比曲类衍生物、其药物组合物、制备方法及用途
|
CN104557600B
(zh)
*
|
2015-01-26 |
2016-05-04 |
苏州明锐医药科技有限公司 |
沙库比曲的制备方法
|
AU2016219362B2
(en)
|
2015-02-11 |
2019-11-14 |
Theravance Biopharma R&D Ip, Llc |
(2S,4R)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
|
TW201632493A
(zh)
|
2015-02-13 |
2016-09-16 |
諾華公司 |
新穎方法
|
EP3259255B1
(en)
|
2015-02-19 |
2020-10-21 |
Theravance Biopharma R&D IP, LLC |
(2r,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
|
WO2016135751A1
(en)
|
2015-02-25 |
2016-09-01 |
Mylan Laboratories Limited |
Novel process for the preparation of sacubitril and its intermediates
|
CN105963296B
(zh)
*
|
2015-03-12 |
2020-01-21 |
深圳信立泰药业股份有限公司 |
一种含有阿利沙坦酯或其盐或其水解产物或其水解产物盐的药物组合物及其用途
|
US10233144B2
(en)
*
|
2015-03-20 |
2019-03-19 |
Crystal Pharmatech Co., Ltd. |
Crystalline form of AHU377, preparation method and use thereof
|
PT3294283T
(pt)
|
2015-05-11 |
2023-06-07 |
Novartis Ag |
Regime de dosagem de sacubitril-valsartan para tratar a insuficiência cardíaca
|
EP3302460A1
(en)
|
2015-05-29 |
2018-04-11 |
Novartis AG |
Sacubitril and valsartan for treating metabolic disease
|
CN104860894B
(zh)
*
|
2015-06-10 |
2017-05-17 |
北京博全健医药科技有限公司 |
一种抗心衰药lcz696的制备方法
|
EP3828175A1
(en)
|
2015-06-12 |
2021-06-02 |
Teva Pharmaceuticals International GmbH |
Solid state forms of trisodium valsartan: sacubitril
|
WO2016203500A2
(en)
|
2015-06-19 |
2016-12-22 |
Actavis Group Ptc Ehf. |
Preparation of sacubitril or salt thereof and novel intermediates in the preparation of sacubitril
|
JP6748123B2
(ja)
*
|
2015-07-02 |
2020-08-26 |
ノバルティス アーゲー |
サクビトリルカルシウム塩
|
WO2017006254A1
(en)
|
2015-07-08 |
2017-01-12 |
Novartis Ag |
Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
|
WO2017009784A1
(en)
|
2015-07-14 |
2017-01-19 |
Cadila Healthcare Limited |
Solid state forms of trisodium salt of valsartan/sacubitril complex and sacubitril
|
WO2017012600A1
(en)
|
2015-07-20 |
2017-01-26 |
Zentiva, K.S. |
A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
|
CN113750102A
(zh)
*
|
2015-07-23 |
2021-12-07 |
拜耳制药股份公司 |
可溶性鸟苷酸环化酶的刺激剂和/或活化剂及其用途
|
WO2017029261A1
(de)
*
|
2015-08-19 |
2017-02-23 |
Bayer Pharma Aktiengesellschaft |
Kombinationspräparat umfassend finerenone und einen nep-inhibitor (sacubitril)
|
WO2017033128A1
(en)
|
2015-08-25 |
2017-03-02 |
Novartis Ag |
Biphenyl-substitued 4-amino-butyric acid derivatives and their use in the synthesis of nep inhibitors
|
US10596151B2
(en)
|
2015-08-28 |
2020-03-24 |
Novartis Ag |
Methods and pharmaceutical compositions for reducing arterial stiffness with a combination of a therapeutic agent blocking the angiotensin receptor and a therapeutic agent inhibiting the NEP enzyme
|
WO2017051326A1
(en)
|
2015-09-23 |
2017-03-30 |
Novartis Ag |
New processes and intermediates useful in synthesis of nep inhibitors
|
WO2017072636A1
(en)
|
2015-10-29 |
2017-05-04 |
Cadila Healthcare Limited |
Pharmaceutical synergistic combination
|
JP7001597B2
(ja)
|
2015-12-10 |
2022-01-19 |
ノバルティス アーゲー |
新規なプロセスおよび中間体
|
WO2017097275A1
(en)
*
|
2015-12-11 |
2017-06-15 |
Zentiva, K.S. |
Solid forms of (2r,4s)-5-(biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2- -methylpentanoic acid ethyl ester, its salts and a preparation method
|
CN106977417A
(zh)
*
|
2016-01-15 |
2017-07-25 |
常州方楠医药技术有限公司 |
一种沙库比曲钠盐的晶型及其制备方法
|
CN108601741B
(zh)
|
2016-02-03 |
2022-05-24 |
诺华股份有限公司 |
有机化合物的盖伦制剂
|
SG11201807591VA
(en)
|
2016-03-08 |
2018-10-30 |
Theravance Biopharma R&D Ip Llc |
Crystalline(2s,4r)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
|
WO2017172795A1
(en)
|
2016-03-28 |
2017-10-05 |
Intra-Cellular Therapies, Inc. |
Novel compositions and methods
|
CN105753733B
(zh)
*
|
2016-04-15 |
2019-06-18 |
苏州晶云药物科技股份有限公司 |
Ahu377的晶型及其制备方法与用途
|
CN105820064A
(zh)
*
|
2016-04-18 |
2016-08-03 |
浙江天宇药业股份有限公司 |
一种联苯基丙氨醇衍生物的合成方法及中间体
|
WO2017191620A1
(en)
*
|
2016-05-06 |
2017-11-09 |
Sun Pharmaceutical Industries Limited |
A crystalline form of a salt of sacubitril and a process of its preparation
|
WO2018007919A1
(en)
|
2016-07-05 |
2018-01-11 |
Novartis Ag |
New process for early sacubitril intermediates
|
CN107602399B
(zh)
*
|
2016-07-11 |
2020-09-25 |
江西东邦药业有限公司 |
一种脑啡肽酶抑制剂中间体的制备方法
|
JP6945619B2
(ja)
*
|
2016-08-17 |
2021-10-06 |
ノバルティス アーゲー |
Nep阻害剤合成のための新規な方法および中間体
|
CN106318988B
(zh)
*
|
2016-08-23 |
2020-11-03 |
迪嘉药业集团有限公司 |
一种lcz696关键中间体的制备方法
|
CN109661386A
(zh)
*
|
2016-09-07 |
2019-04-19 |
诺瑞特国际药业股份有限公司 |
沙库比曲钠盐新晶型
|
CN106478437A
(zh)
*
|
2016-09-27 |
2017-03-08 |
南通常佑药业科技有限公司 |
一种γ‑氨基戊酸酯衍生物的制备方法
|
CN106496055A
(zh)
*
|
2016-10-09 |
2017-03-15 |
杭州科巢生物科技有限公司 |
一种抗心衰新药的关键组分沙库比曲的新合成方法
|
EP3522886A4
(en)
|
2016-10-10 |
2020-02-19 |
Laurus Labs Limited |
STABLE AMORPHE FORM OF THE SACUBITRIL VALSARTAN TRINATRIUM COMPLEX AND METHOD FOR THE PRODUCTION THEREOF
|
US10995060B2
(en)
|
2016-10-28 |
2021-05-04 |
Biocon Limited |
Amorphous Trisodium Sacubitril Valsartan and process for its preparation
|
WO2018116203A1
(en)
|
2016-12-23 |
2018-06-28 |
Novartis Ag |
New process for early sacubitril intermediates
|
CN106831473B
(zh)
*
|
2017-02-22 |
2019-07-16 |
江西瑞雅药业有限公司 |
3-酰胺基-4-(2’-烷氧基-4-联苯基)丁酸衍生物及其制备方法、药物组合物
|
WO2018153895A1
(de)
|
2017-02-22 |
2018-08-30 |
Bayer Pharma Aktiengesellschaft |
Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit einem inhibitor der neutralen endopeptidase und/oder einem angiotensin ii rezeptor-antagonisten
|
WO2018178295A1
(en)
|
2017-03-31 |
2018-10-04 |
Alfred E. Tiefenbacher (Gmbh & Co. Kg) |
Stable hot-melt extrudate containing valsartan and sacubitril
|
PL3658122T3
(pl)
|
2017-07-28 |
2021-10-18 |
Synthon B.V. |
Kompozycja farmaceutyczna zawierająca sakubitryl i walsartan
|
US20200276129A1
(en)
|
2017-10-13 |
2020-09-03 |
Alfred E. Tiefenbacher (Gmbh & Co. Kg) |
Tablet containing valsartan and sacubitril
|
CN108530371B
(zh)
*
|
2017-12-27 |
2020-09-01 |
浙江天宇药业股份有限公司 |
一种沙库比曲钠盐、沙库比曲游离酸与乙酸的共晶物、其晶型、晶型的制备方法及用途
|
US11839614B2
(en)
|
2018-01-31 |
2023-12-12 |
Intra-Cellular Therapies, Inc. |
Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression
|
UY38072A
(es)
|
2018-02-07 |
2019-10-01 |
Novartis Ag |
Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
|
GB201810326D0
(en)
*
|
2018-06-22 |
2018-08-08 |
Johnson Matthey Plc |
Crystalline form of sacubitril, its preparation and use
|
US20210177803A1
(en)
|
2018-08-23 |
2021-06-17 |
Novartis Ag |
New pharmaceutical use for the treatment of heart failure
|
WO2020039394A1
(en)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
New drug combinations
|
CN109503404A
(zh)
*
|
2018-12-28 |
2019-03-22 |
凯瑞斯德生化(苏州)有限公司 |
一种lcz-696关键中间体的制备方法
|
CN110128298B
(zh)
*
|
2019-06-13 |
2021-08-03 |
南京一心和医药科技有限公司 |
一种沙库巴曲中间体的合成方法
|
CN113135836A
(zh)
*
|
2020-01-20 |
2021-07-20 |
鲁南制药集团股份有限公司 |
一种沙库巴曲钙盐的制备方法
|
CN111253425B
(zh)
*
|
2020-02-21 |
2022-04-29 |
常州南京大学高新技术研究院 |
一种1,3-双[2-(3,4-环氧环己基)乙基]四甲基二硅氧烷的合成方法
|
JP7064527B2
(ja)
*
|
2020-05-01 |
2022-05-10 |
ノバルティス アーゲー |
サクビトリルカルシウム塩
|
KR20220012821A
(ko)
|
2020-07-23 |
2022-02-04 |
주식회사 종근당 |
이중 작용 복합 화합물의 결정형 및 이의 제조방법
|
CN112661671B
(zh)
*
|
2020-12-22 |
2022-04-22 |
江苏阿尔法药业股份有限公司 |
一种沙库巴曲中间体的制备方法
|
WO2022224274A1
(en)
|
2021-04-20 |
2022-10-27 |
Mylan Laboratories Limited |
Polymorphic forms of sacubitril-telmisartan (1:1)
|